Heidi Wang

CEO
OBI Pharma
​

Dr. Heidi Wang is an experienced drug developer with more than 30 years of global pharmaceutical and biotech industry experience. With deep expertise in Oncology, Virology, Immunology, etc., Heidi has a proven record of working or leading teams to obtain approvals for 10 New Molecule Entities, many were first-in-class drugs, as well as more than 30 supplemental applications worldwide. 
Heidi had a long career at Bristol Myers Squibb Company (BMS, a Fortune 500 company), leading teams in the US headquarter and in multiple countries, including China. Other than delivering new drug approvals globally, Heidi had a chance to transform BMS’ processes and mindset to optimize company’s portfolio acceleration, enable global simultaneous submissions and approvals of life saving medicines, and shape company’s 2030 China strategy, etc.
After joining OBI Pharma as the CEO in 2023, Heidi changed the company’s culture, grew talent, encouraged an “inclusive” mindset, reshaped the portfolio with a laser focus on Antibody-Drug-Conjugate (ADC) assets, and drove the development of unique ADC enabling technologies that are likely “best-in-class”.
 
Heidi’s twin passions are to bring new medicines to patients worldwide and to give back. Hence, she shaped both BMS and OBI Pharma’s global drug development strategy and processes, converted colleagues’ mindset to think globally from early stages of clinical development, enabled acceleration in submissions and approvals, and ensured success in reimbursement and commercial areas. She volunteers as a mentor and advisor to colleagues and organizations in the US and Taiwan to give back to the community.  
 
Heidi received her B.S. degree from Fu-Jen University in Taiwan. After receiving her M.S. and Ph.D. degrees in Molecular Biology and Virology from University of Notre Dame in Notre Dame, IN, USA, Heidi had postdoctoral training in Cancer Biology at the Cold Spring Harbor Laboratory in New York, USA.

 

Speech title & Synopsis

Panel Discussion

as Moderator